Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
08
01
2023
revised:
21
04
2023
accepted:
16
06
2023
pmc-release:
01
03
2024
medline:
4
9
2023
pubmed:
21
6
2023
entrez:
21
6
2023
Statut:
ppublish
Résumé
Sex and racial/ethnic identity-specific cut-points for validating tobacco use using Wave 1 (W1) of the Population Assessment of Tobacco and Health (PATH) Study were published in 2020. The current study establishes predictive validity of the W1 (2014) urinary cotinine and total nicotine equivalents-2 (TNE-2) cut-points on estimating Wave 4 (W4; 2017) tobacco use. For exclusive and polytobacco cigarette use, weighted prevalence estimates based on W4 self-report alone and with exceeding the W1 cut-point were calculated to identify the percentage missed without biochemical verification. Sensitivity and specificity of W1 cut-points on W4 self-reported tobacco use status were examined. ROC curves were used to determine the optimal W4 cut-points to distinguish past 30-day users from non-users, and evaluate whether the cut-points significantly differed from W1. Agreement between W4 self-reported use and exceeding the W1 cut-points was high overall and when stratified by demographic subgroups (0.7%-4.4% of use was missed if relying on self-report alone). The predictive validity of using the W1 cut-points to classify exclusive cigarette and polytobacco cigarette use at W4 was high (>90% sensitivity and specificity, except among polytobacco Hispanic smokers). Cut-points derived using W4 data did not significantly differ from the W1-derived cut-points [e.g., W1 exclusive = 40.5 ng/mL cotinine (95% confidence interval, CI: 26.1-62.8), W4 exclusive = 29.9 ng/mL cotinine (95% CI: 13.5-66.4)], among most demographic subgroups. The W1 cut-points remain valid for biochemical verification of self-reported tobacco use in W4. Findings from can be used in clinical and epidemiologic studies to reduce misclassification of cigarette smoking status.
Sections du résumé
BACKGROUND
Sex and racial/ethnic identity-specific cut-points for validating tobacco use using Wave 1 (W1) of the Population Assessment of Tobacco and Health (PATH) Study were published in 2020. The current study establishes predictive validity of the W1 (2014) urinary cotinine and total nicotine equivalents-2 (TNE-2) cut-points on estimating Wave 4 (W4; 2017) tobacco use.
METHODS
For exclusive and polytobacco cigarette use, weighted prevalence estimates based on W4 self-report alone and with exceeding the W1 cut-point were calculated to identify the percentage missed without biochemical verification. Sensitivity and specificity of W1 cut-points on W4 self-reported tobacco use status were examined. ROC curves were used to determine the optimal W4 cut-points to distinguish past 30-day users from non-users, and evaluate whether the cut-points significantly differed from W1.
RESULTS
Agreement between W4 self-reported use and exceeding the W1 cut-points was high overall and when stratified by demographic subgroups (0.7%-4.4% of use was missed if relying on self-report alone). The predictive validity of using the W1 cut-points to classify exclusive cigarette and polytobacco cigarette use at W4 was high (>90% sensitivity and specificity, except among polytobacco Hispanic smokers). Cut-points derived using W4 data did not significantly differ from the W1-derived cut-points [e.g., W1 exclusive = 40.5 ng/mL cotinine (95% confidence interval, CI: 26.1-62.8), W4 exclusive = 29.9 ng/mL cotinine (95% CI: 13.5-66.4)], among most demographic subgroups.
CONCLUSIONS
The W1 cut-points remain valid for biochemical verification of self-reported tobacco use in W4.
IMPACT
Findings from can be used in clinical and epidemiologic studies to reduce misclassification of cigarette smoking status.
Identifiants
pubmed: 37342065
pii: 727388
doi: 10.1158/1055-9965.EPI-22-1228
pmc: PMC10527251
mid: NIHMS1912847
doi:
Substances chimiques
Cotinine
K5161X06LL
Biomarkers
0
Tobacco Smoke Pollution
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1233-1241Subventions
Organisme : NIDA NIH HHS
ID : HHSN271201100027C
Pays : United States
Organisme : NIDA NIH HHS
ID : HHSN271201600001C
Pays : United States
Informations de copyright
©2023 American Association for Cancer Research.
Références
Vital Health Stat 2. 1969 Jan;(31):1-24
pubmed: 5306564
JAMA. 1998 Jul 8;280(2):135-9
pubmed: 9669785
Cancer Epidemiol Biomarkers Prev. 2020 Aug;29(8):1673-1678
pubmed: 32532831
Nicotine Tob Res. 2022 Mar 26;24(5):768-777
pubmed: 35348786
Nicotine Tob Res. 2023 Mar 22;25(4):616-623
pubmed: 35348750
Nicotine Tob Res. 2019 Apr 17;21(5):699-700
pubmed: 29722885
Epidemiol Rev. 1996;18(2):188-204
pubmed: 9021312
Tob Control. 2017 Jul;26(4):371-378
pubmed: 27507901
JAMA. 1996 Apr 24;275(16):1233-40
pubmed: 8601954
Biomarkers. 2020 Feb;25(1):27-33
pubmed: 31686544
Am J Public Health. 1987 Nov;77(11):1435-8
pubmed: 3661797
Nicotine Tob Res. 2022 Mar 26;24(5):761-767
pubmed: 34718769
Am J Epidemiol. 2009 Jan 15;169(2):236-48
pubmed: 19019851
Pharmacol Rev. 2005 Mar;57(1):79-115
pubmed: 15734728
Nicotine Tob Res. 2020 Jun 12;22(7):1086-1097
pubmed: 31570931
J Natl Cancer Inst. 2002 Jan 16;94(2):108-15
pubmed: 11792749
Am J Public Health. 1994 Jul;84(7):1086-93
pubmed: 8017530
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1175-1184
pubmed: 33827982
Nicotine Tob Res. 2020 Feb 6;22(2):288-292
pubmed: 30852610
Clin Pharmacol Ther. 2006 May;79(5):480-8
pubmed: 16678549
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):291-302
pubmed: 28151705
Nicotine Tob Res. 2020 Oct 8;22(10):1744-1747
pubmed: 32391548
Prev Med. 1995 Mar;24(2):171-9
pubmed: 7597020
J Pharmacol Exp Ther. 2004 Sep;310(3):1208-15
pubmed: 15084646
Pharmacogenomics J. 2014 Jun;14(3):229-34
pubmed: 23959274